Renal Denervation Therapy for Resistant Hypertension in Type 2 Diabetes Mellitus

Renal Denervation Therapy for Resistant Hypertension in Type 2 Diabetes Mellitus

To demonstrate the efficacy of renal denervation therapy in treating resistant hypertension and its effect on glucose metabolism in patients with type 2 diabetes mellitus

Inclusion Criteria:

• Age ranges from 18 to 70 years inclusive
• Essential hypertension
• Office Systolic BP (SBP) ≥ 150 mmHg or Diastolic BP (DBP) ≥ 90mmHg
• 3 or more anti-hypertensive medications of different classes, including a diuretic, or documented intolerance to multiple medications
• Type 2 Diabetes Mellitus on oral hypoglycaemic agent (OHA)
• 2 functional kidneys; eGFR ≥ 45 mL/min/1.73m² (MDRD formula)
• Suitable renal anatomy compatible with the endovascular denervation procedure

Exclusion Criteria:

• Individual has renal artery anatomy that is ineligible for treatment including:
• Patients with secondary hypertension
• Myocardial infarction, unstable angina pectoris, cerebrovascular accident within 6 months
• Patient with type 1 diabetes mellitus
• Patient on insulin due to oral drug failure
• Renovascular abnormalities (including severe renal artery stenosis, previous renal stenting or angioplasty, or known dual renal arteries)
• Pregnancy
• Patient with any implantable device incompatible with radiofrequency energy delivery
• Hemodynamically significant valvular heart disease for which reduction of BP would be considered hazardous
• Any serious medical condition, which in the opinion of the investigator, may limit the life expectancy of patients or adversely